On Apr. 28, 2021, Innovation Pharma announced that enrollment had surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients.

Brilacidin was the only non-peptidic defensin-mimetic drug candidate in the in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.